Wednesday, October 01, 2008 2:57:28 PM
Recent HCM News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 10:21:26 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 10:07:14 AM
- HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China • GlobeNewswire Inc. • 03/23/2026 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2026 10:08:56 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/09/2026 10:12:01 AM
- HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China • GlobeNewswire Inc. • 03/09/2026 09:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2026 11:03:29 AM
- Intended Retirement of Independent Non-executive Director and changes of composition of board committees • GlobeNewswire Inc. • 03/06/2026 08:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 12:51:08 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2026 12:27:36 PM
- HUTCHMED Reports 2025 Full Year Results and Business Updates • GlobeNewswire Inc. • 03/05/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 11:04:25 AM
- HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors • GlobeNewswire Inc. • 03/04/2026 08:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/06/2026 11:06:10 AM
- HUTCHMED to Announce 2025 Final Results • GlobeNewswire Inc. • 02/06/2026 08:30:00 AM

